438 related articles for article (PubMed ID: 3708604)
21. [Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].
Chaná P; Fierro A; Reyes-Parada M; Sáez-Briones P
Rev Med Chil; 2003 Jun; 131(6):623-31. PubMed ID: 12942590
[TBL] [Abstract][Full Text] [Related]
22. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
[TBL] [Abstract][Full Text] [Related]
23. Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa.
Goetz CG; Tanner CM; Gilley DW; Klawans HL
Neurology; 1989 Nov; 39(11 Suppl 2):63-6; discussion 72-3. PubMed ID: 2586764
[TBL] [Abstract][Full Text] [Related]
24. Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease.
Mark MH; Sage JI
Ann Clin Lab Sci; 1989; 19(2):101-6. PubMed ID: 2665626
[TBL] [Abstract][Full Text] [Related]
25. An open multicenter long-term treatment evaluation of Sinemet CR. Sinemet CR Multicenter Study Group.
Bush DF; Liss CL; Morton A
Neurology; 1989 Nov; 39(11 Suppl 2):101-4; discussion 105. PubMed ID: 2685646
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study.
Pahwa R; Marjama J; McGuire D; Lyons K; Zwiebel F; Silverstein P; Ward R; Koller WC
Mov Disord; 1996 Jul; 11(4):427-30. PubMed ID: 8813223
[TBL] [Abstract][Full Text] [Related]
27. Controlled-release carbidopa/levodopa in the treatment of Parkinsonism.
Hutton JT; Dippel RL; Bianchine JR; Strahlendorf HK; Meyer PG
Clin Neuropharmacol; 1984; 7(2):135-9. PubMed ID: 6375861
[TBL] [Abstract][Full Text] [Related]
28. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
Cedarbaum JM; Breck L; Kutt H; McDowell FH
Neurology; 1987 Feb; 37(2):233-41. PubMed ID: 3808304
[TBL] [Abstract][Full Text] [Related]
29. [Drug therapy of Parkinson's disease].
Zhou XD
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):193-6. PubMed ID: 4075905
[No Abstract] [Full Text] [Related]
30. Long-term clinical efficacy of Sinemet CR in patients with Parkinson's disease.
Rodnitzky RL; Dickins QS; Dobson J
Neurology; 1989 Nov; 39(11 Suppl 2):92-5; discussion 95. PubMed ID: 2586769
[TBL] [Abstract][Full Text] [Related]
31. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
32. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Fleming SM; Delville Y; Schallert T
Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
[TBL] [Abstract][Full Text] [Related]
33. Response to Sinemet 25/100 in Parkinson's disease.
Ulm G; Gerdes U; Lehmann K
Adv Neurol; 1984; 40():541-7. PubMed ID: 6695634
[No Abstract] [Full Text] [Related]
34. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
[TBL] [Abstract][Full Text] [Related]
35. [Advanced course of Parkinson disease. Little improved motion with continuous intestinal levodopa administration].
Oberpichler-Schwenk H
Med Monatsschr Pharm; 2005 Jul; 28(7):245-6. PubMed ID: 16038123
[No Abstract] [Full Text] [Related]
36. Experiences with Sinemet CR in the Paracelsus-Elena-Klinik.
Ulm G; Gerdes U; Haagen K
Neurology; 1989 Nov; 39(11 Suppl 2):85-7; discussion 95. PubMed ID: 2586768
[TBL] [Abstract][Full Text] [Related]
37. Sinemet - 25/100.
Med Lett Drugs Ther; 1980 Jun; 22(12):51. PubMed ID: 7374623
[No Abstract] [Full Text] [Related]
38. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
Reichmann H; Emre M
Expert Rev Neurother; 2012 Feb; 12(2):119-31. PubMed ID: 22288667
[TBL] [Abstract][Full Text] [Related]
39. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J
Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
Yeh KC; August TF; Bush DF; Lasseter KC; Musson DG; Schwartz S; Smith ME; Titus DC
Neurology; 1989 Nov; 39(11 Suppl 2):25-38. PubMed ID: 2685649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]